Condition

Sarcomatoid Mesothelioma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions8

Lead sponsors shown2

Clinical trials

3 shown

Pembrolizumab in Treating Patients With Malignant MesotheliomaNCT02399371 · 2015-03-31

COMPLETED

Tivantinib in Treating Patients With Previously Treated Malignant MesotheliomaNCT01861301 · 2013-01-01

TERMINATED

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural MesotheliomaNCT01064648 · 2010-03-15

ACTIVE_NOT_RECRUITING

Common interventions

Laboratory Biomarker AnalysisOTHER3 Cediranib MaleateDRUG1 CisplatinDRUG1 PembrolizumabBIOLOGICAL1 Pemetrexed DisodiumDRUG1 Pharmacogenomic StudyOTHER1 Placebo AdministrationOTHER1 TivantinibDRUG1

Leading sponsors

National Cancer Institute (NCI) 2 University of Chicago 1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

Phase mix

PHASE23

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.